Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome (PRIME)
The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome （PRIME Study）
Sponsor: Shoichi Maruyama MD PhD
This PHASE3 trial investigates Glomerulonephritis, Membranous and Nephrotic Syndrome，Idiopathic and is currently actively recruiting participants. Shoichi Maruyama MD PhD leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Mar 2025 — Present [monthly]
Recruiting PHASE3
-
Nov 2024 — Mar 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shoichi Maruyama MD PhD
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anjo, Japan , Asahikawa, Japan , Fukuoka, Japan , Hamamatsu, Japan , Kanazawa, Japan , Kasugai, Japan , Kumamoto, Japan , Kurume, Japan , Kyoto, Japan , Kōnan, Japan and 6 more locations